CCO Annual Update
HIV/AIDS Annual Update 2004
Positive and Negative Factors Influencing HIV-Host Cell Interplay |
Module 1 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Effect of Host Cell Cycle on Viral Entry and Replication
- Viral Dissemination in the Host
- Viral Persistence: Virus Life Cycle in Macrophages
- Cellular Proteins and Viral Replication
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the role of cellular proteins in viral pathogenesis. Discuss the role of HIV accessory proteins. Review new concepts in viral pathogenesis.
|
Immunopathogenesis: Innate Immunity |
Module 2 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Innate and Adaptive Immune Systems
- Innate and Adaptive Immune Systems (Cont.)
- Cellular Components of Innate Immunity With Anti-HIV Activity
- Cellular Components of Innate Immunity With Anti-HIV Activity (Cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the anti-HIV cellular immune factors. Detail how the innate immune system provides antiviral immunity. Describe the components of and differences between the innate and adaptive immune systems.
|
Treatment of Antiretroviral-Naive Patients |
Module 3 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- When to Start
- What to Start With
- What to Start With (Cont.)
- What to Start With (Cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the options for initial antiretroviral therapy. Discuss when to start antiretroviral therapy. Describe the management of treatment intolerance and initial failure.
|
New Insights Into HIV-1 Drug Resistance |
Module 4 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Epidemiology of Drug Resistance
- The K65R Story
- Tyranny of the Minority
- A Random Walk in TAM-Land
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss interactions among drug-resistance mutations. Describe the importance of minor variants in determining response to treatment. Review the changing epidemiology of drug resistance.
|
Managing Cardiovascular Risk in Patients With HIV Infection |
Module 5 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- HAART and Cardiovascular Risk
- Evaluation of Dyslipidemia in Patients Receiving HAART
- Management of Dyslipidemia in Patients Receiving HAART
- Beyond the Guidelines
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the evaluation of dyslipidemia in patients receiving HAART. Review the epidemiology of coronary heart disease in patients with HIV infection in the HAART era. Discuss the management of dyslipidemia in patients receiving HAART.
|
HIV Treatment in Challenging Populations |
Module 6 of 10 |
|
Program Director: John P. Phair, MD
- Kimberly Y. Smith, MD, MPH
|
|
|
Topics covered include:
- Introduction
- Black Communities
- Black Communities (Cont.)
- Disease Progression
- Differences in Treatment Response
Learning Objectives
Upon completion of this activity, participants should be able to:
Review relevant studies describing novel management approaches in these populations. Describe issues that compromise the effectiveness of treatment in ethnic minorities, injection-drug users, and prison populations. Discuss strategies to improve effectiveness of treatment/management of these populations.
|
Pharmacology Update: Drug-Drug Interactions and Ethnic and Sex Differences |
Module 7 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Drug-Drug Interactions
- Drug-Drug Interactions (Cont.)
- Drug-Drug Interactions (Cont.)
- Drug-Drug Interactions (Cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the impact of ethnicity on antiretroviral metabolism. Review drug-drug interactions of antiretroviral medications and recommended dose adjustments. Describe the impact of sex on antiretroviral metabolism.
|
Update on AIDS-Related Malignancies |
Module 8 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Kaposi's Sarcoma
- Treatment of AIDS-Related KS
- AIDS-Related Lymphoma
- AIDS-Related Lymphoma (cont.)
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the diagnosis and treatment of the different non-AIDS-defining malignancies in patients with HIV/AIDS. Explain why HAART is the treatment of choice for AIDS-related Kaposi's sarcoma. Identify the best approach to treating AIDS-related lymphoma based on new research.
|
Treatment of Viral Hepatitis Coinfection |
Module 9 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Epidemiology of HCV/HIV Coinfection
- Diagnosis of HCV Infection in HIV-Seropositive Individuals
- HCV: Pathogenic Interactions
- Natural History of HCV and HIV
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the approach to treatment of coinfected patients, including management of antiretroviral therapy. Describe the diagnostic modalities for patients coinfected with HBV or HCV. Discuss the complications of therapy for HBV and HCV coinfection in patients with HIV (including flares).
|
Solid Organ Transplantation in HIV-Infected Recipients in the HAART Era |
Module 10 of 10 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Why Now?
- Preliminary Data Prior to and Since the Introduction of HAART
- Special Clinical Considerations
- Future Directions: NIH-Funded Multisite Study
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the status of solid organ transplantation in the United States and Europe. Describe future directions in solid organ transplantation. Describe the challenges to solid organ transplantation in HIV-infected patients.
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Pharmacist and nursing credit provided through the cosponsorship of Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|